| Treatment with nesiritide, a recombinant B-type natriuretic Peptide, reduces vascular remodeling following balloon-induced endothelial injuries in rabbits. | |
| | |
MedLine Citation:
|
PMID: 21079380 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Re-stenosis or remodeling of coronary and peripheral arteries remains a major complication following balloon-angioplasty or stenting. This study was designed to investigate the effect of nesiritide, a recombinant B-type natriuretic peptide (BNP), on vascular remodeling following balloon-induced endothelial injuries. Twenty-eight male New Zealand rabbits were divided into nesiritide-treated (0.1 mg/kg/day, sc, for 4 weeks, n = 10), saline-treated control (n = 10) and sham-operated groups (n = 8). In the nesiritide and control groups, a balloon catheter was inserted to the right iliac artery to induce injuries. Vascular endothelial growth factor (VEGF) was measured by immunohistochemistry. The area under internal elastic membrane of the arterial wall (643.2 ± 134.1 vs 493.7 ± 139.3 µm(2), p < 0.05) and the area under external elastic membrane (1495.1 ± 204.9 vs 1265.9 ± 232.6 µm(2), p < 0.05) in the nesiritide group were greater than those in the control group, but were smaller than those in the sham-operated group (p < 0.05). The stenosis ratio was lower in the nesiritide group than in the control group (18.7 ± 7.7% vs 38.0 ± 8.3%, p < 0.01). Importantly, the VEGF expression rate was significantly lower in the nesiritide group than in the control group (42.2 ± 8.8% vs 56.1 ± 13.1%, p < 0.05), while there were no signs of VEGF expression in the non-injured arteries of the three groups. In conclusion, nesiritide treatment reduces the stenosis of the rabbit iliac artery following balloon-induced endothelial injuries probably by decreasing VEGF expression. |
| | |
Authors:
|
Shu-Qin Liu; Yan-Yun Yu; Hong-Wen Xie; Ke Yu; Le-Xin Wang |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: The Tohoku journal of experimental medicine Volume: 222 ISSN: 1349-3329 ISO Abbreviation: Tohoku J. Exp. Med. Publication Date: 2010 Nov |
Date Detail:
|
Created Date: 2010-11-16 Completed Date: 2011-02-17 Revised Date: 2013-01-03 |
Medline Journal Info:
|
Nlm Unique ID: 0417355 Medline TA: Tohoku J Exp Med Country: Japan |
Other Details:
|
Languages: eng Pagination: 219-23 Citation Subset: IM |
Affiliation:
|
Department of Cardiology, Liaocheng People's Hospital and Liaocheng Clinical School of Taishan Medical University, Shandong, PR China. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angioplasty, Balloon
/
adverse effects* Animals Blood Vessels / drug effects*, injuries, pathology, physiology Constriction, Pathologic / drug therapy, etiology, metabolism, pathology Drug Evaluation, Preclinical Endothelium, Vascular / drug effects*, metabolism, pathology Iliac Artery / drug effects, injuries, metabolism, pathology Male Natriuretic Agents / pharmacology, therapeutic use Natriuretic Peptide, Brain / analogs & derivatives, pharmacology, therapeutic use* Rabbits Recombinant Proteins / pharmacology, therapeutic use Vascular Diseases / drug therapy*, etiology*, metabolism, pathology Vascular Endothelial Growth Factor A / metabolism |
| Chemical | |
Reg. No./Substance:
|
0/Natriuretic Agents; 0/Recombinant Proteins; 0/Vascular Endothelial Growth Factor A; 114471-18-0/Natriuretic Peptide, Brain |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Clorgyline inhibits orexin-a-induced arousal in layer-type chicks.
Next Document: Validated methods of cough assessment: a systematic review of the literature.